FRISCO, Texas / Feb 28, 2023 / Business Wire / Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that Dirk Allison, Chairman, President and Brian Poff, Executive Vice President and Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.
In connection with the virtual conference, there will be a live broadcast and replay of the Company’s presentation available under the Investor Relations section of the Company’s website, www.addus.com, starting at 9:20 a.m. Eastern Time / 8:20 a.m. Central Time on Tuesday, March 14, 2023. An online replay will also be available on the Company’s website for one month, beginning approximately one hour following the conclusion of the live broadcast.
About Addus HomeCare
Addus HomeCare is a provider of home care services that primarily include personal care services that assist with activities of daily living, as well as hospice and home health services. Addus HomeCare’s consumers are primarily persons who, without these services, are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Addus HomeCare’s payor clients include federal, state and local governmental agencies, managed care organizations, commercial insurers and private individuals. Addus HomeCare currently provides home care services to approximately 46,500 consumers through 202 locations across 22 states. For more information, please visit www.addus.com.
Last Trade: | US$101.25 |
Daily Change: | 0.25 0.25 |
Daily Volume: | 153,572 |
Market Cap: | US$1.840B |
November 04, 2024 August 05, 2024 June 28, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load